CALGARY, ALBERTA--(CCNMatthews - Aug. 8, 2005) - Resverlogix Corp. (TSX:RVX) announced today that on behalf of its wholly owned subsidiary, RVX Therapeutics, it has filed a patent application covering a unique and expanded application of its cardiovascular technology. RVX Therapeutics has discovered pharmaceutical compounds which have the potential to be used with medical devices such as drug-eluting stents.
